These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 27793187

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M.
    Nat Commun; 2016 May 19; 7():11363. PubMed ID: 27193833
    [Abstract] [Full Text] [Related]

  • 3. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM.
    Clin Cancer Res; 2016 Apr 01; 22(7):1674-1686. PubMed ID: 26597303
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
    Narvaez AJ, Ber S, Crooks A, Emery A, Hardwick B, Guarino Almeida E, Huggins DJ, Perera D, Roberts-Thomson M, Azzarelli R, Hood FE, Prior IA, Walker DW, Boyce R, Boyle RG, Barker SP, Torrance CJ, McKenzie GJ, Venkitaraman AR.
    Cell Chem Biol; 2017 Aug 17; 24(8):1017-1028.e7. PubMed ID: 28807782
    [Abstract] [Full Text] [Related]

  • 6. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN, Louwen F, Zimmer B, Yuan J.
    Oncotarget; 2015 Mar 30; 6(9):6611-26. PubMed ID: 25483104
    [Abstract] [Full Text] [Related]

  • 7. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC, Sun SH, Wang FF.
    Cell Signal; 2011 Nov 30; 23(11):1816-23. PubMed ID: 21726628
    [Abstract] [Full Text] [Related]

  • 8. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
    Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC.
    Cell; 2015 Jul 02; 162(1):146-59. PubMed ID: 26140595
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
    Xu Y, Zong S, Gao X, Zhang H, Wang B, Li P, Liu T, Li S.
    Gene; 2019 Mar 10; 688():1-6. PubMed ID: 30415007
    [Abstract] [Full Text] [Related]

  • 12. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y, Yang G, Hong Y.
    Cancer Lett; 2015 Feb 28; 357(2):520-6. PubMed ID: 25499080
    [Abstract] [Full Text] [Related]

  • 13. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
    Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X.
    J Clin Invest; 2020 Apr 01; 130(4):1752-1766. PubMed ID: 31874110
    [Abstract] [Full Text] [Related]

  • 14. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB, Huang J, Xie C, Li X, Liu L, He J, Pan H, Huang L, Fan XX, Yao XJ, Xie Y, Li N, Liu L, He JX, Leung EL.
    Oncol Rep; 2016 Jul 01; 36(1):365-75. PubMed ID: 27121230
    [Abstract] [Full Text] [Related]

  • 15. Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Son KH, Kim MY, Shin JY, Kim JO, Kang JH.
    Anticancer Res; 2021 Oct 01; 41(10):4807-4820. PubMed ID: 34593430
    [Abstract] [Full Text] [Related]

  • 16. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
    Huang S, Ren X, Wang L, Zhang L, Wu X.
    Cancer Prev Res (Phila); 2011 May 01; 4(5):666-73. PubMed ID: 21543344
    [Abstract] [Full Text] [Related]

  • 17. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA, De Wever O, Kronenberger P, Van Deun J, Noor A, Singh K, Teugels E, Chen G, Bracke M, De Grève J.
    Oncotarget; 2015 Aug 21; 6(24):20132-44. PubMed ID: 25992771
    [Abstract] [Full Text] [Related]

  • 18. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
    Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C, Sun Z, Pang X.
    Biochem Pharmacol; 2020 Jul 21; 177():113960. PubMed ID: 32298693
    [Abstract] [Full Text] [Related]

  • 19. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
    Wang Z, Yin M, Chu P, Lou M.
    Aging (Albany NY); 2019 Sep 04; 11(17):7187-7196. PubMed ID: 31484165
    [Abstract] [Full Text] [Related]

  • 20. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.